To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.
Allergy to liraglutide, orlistat or excipients
Severe liver and kidney dysfunction: ALT or AST> three times the upper limit of normal, or eGFR <30 mL/min
Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers
Parallel
liraglutide monotherapy
Drugliraglutide monotherapy
liraglutide combined with orlistat
Drugcombination therapy
weight loss
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
